Discounted Cash Flow (DCF) Analysis Levered

Xenetic Biosciences, Inc. (XBIOW)

$13

+0.52 (+4.17%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
Revenue (%)
Operating Cash Flow ----------
Operating Cash Flow (%)
Capital Expenditure ----------
Capital Expenditure (%)
Free Cash Flow ----------

Weighted Average Cost Of Capital

Share price $ 13
Beta 2.641
Diluted Shares Outstanding 14.22
Cost of Debt
Tax Rate 2.53
After-tax Cost of Debt 4.87%
Risk-Free Rate
Market Risk Premium
Cost of Equity 16.793
Total Debt -
Total Equity 184.92
Total Capital 184.92
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
Operating Cash Flow ----------
Capital Expenditure ----------
Free Cash Flow ----------
WACC
PV LFCF -----
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 16.79
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -13.10
Equity Value -
Shares Outstanding 14.22
Equity Value Per Share -